Abstracts Archive - Page 250 of 2425 - ACR Meeting Abstracts

Abstract Number: 0737 • ACR Convergence 2023
Unraveling Pathophysiology and Hematopoiesis of VEXAS Syndrome by Multi-omics Analysis and Targeted Gene Editing
Corrado Campochiaro¹, Raffaella Molteni², Martina Fiumara³, Alessandro Tomelleri⁴, Elisa Diral⁵, Davide Stefanoni², Angelica Varesi³, Alessandra Weber³, Roberta Alfieri⁶, Luisa Albano³, Maddalena Panigada², Eleonora Cantoni², Daniele Canarutto³, Luca Basso-Ricci³, Pamela Quaranta³, Angelo D’Alessandro⁷, marco Matucci Cerinic⁸, Raffaella Di Micco³, Serena Scala³, Alessandro Aiuti³, Fabio Ciceri⁵, Ivan Merelli³, Lorenzo Dagna⁹, Simone Cenci², Luigi Naldini³, Samuele Ferrari³ and Giulio Cavalli², ¹IRCCS San Raffaele Hospital, Unit of Immunology, Rheumatology, Allergy and Rare Disease. Vita-Salute San Raffaele University, Milan, Italy, ²Division of Genetics and Cell Biology, IRCCS San Raffaele Scientific Institute, Milan, Italy, ³San Raffaele Telethon Institute for Gene Therapy, IRCCS San Raffaele Scientific Institute, Milan, Italy, ⁴Unit of Immunology, Rheumatology, Allergy and Rare Diseases, San Raffaele Scientific Institute, Milano, Italy, ⁵Unit of Haematology and Bone Marrow Transplantation, IRCCS San Raffaele Hospital, Milan, Italy, ⁶Institute for Biomedical Technologies, National Research Council, Segrate, Italy, ⁷Department of Biochemistry and Molecular Genetics, University of Colorado Denver - Anschutz Medical Campus, Aurora, CO, ⁸Unit of Immunology, Rheumatology, Allergy and Rare diseases, IRCCS San Raffaele Hospital, Milan, Milan, Italy, ⁹Department of Internal Medicine, IRCCS San Raffaele Hospital and Vita-Salute San Raffaele University, Milan, Italy
Background/Purpose: VEXAS syndrome is an adult-onset, X-linked, life-threatening, autoinflammatory and hematological disease caused by somatic mutation in UBA1 gene. To understand its pathophysiology, we aimed…
Abstract Number: 1265 • ACR Convergence 2023
Changes in the Endocannabinoid Tone in Rheumatoid Arthritis and Osteoarthritis – Discovery of a Novel Target for the Treatment of Pain and Inflammation?
Jost Klawitter¹, Andrew Clauw¹, Jennifer Seifert¹, Jelena Klawitter¹, Bridget Tompson¹, Cristina Sempio¹, Uwe Christians¹ and Larry Moreland², ¹University of Colorado Anschutz Medical Campus, Aurora, CO, ²University of Colorado, Denver, CO

Background/Purpose: Inflammation is a complicated physiological process that results in a variety of disorders. Several inflammatory mediators are produced during this process, which is responsible…
Abstract Number: 1092 • ACR Convergence 2023
Improving Screening of Lupus Nephritis in Patients with Systemic Lupus Erythematous
Lilian Otalora Rojas¹, Gurjit S Kaeley² and Myint Thway³, ¹University of Florida, Ponte Vedra Beach, FL, ²University of Florida College of Medicine – Jacksonville, Ponte Vedra Beach, FL, ³UF Jacksonville, Ponte Vedra, FL
Background/Purpose: Nephritis remains one of the most devastating complications of Systemic lupus erythematosus (SLE). Lupus nephritis (LN) significantly reduces overall survival to approximately 88% at…
Abstract Number: 1276 • ACR Convergence 2023
Multimorbidity Burden Predicts Lower Likelihood of Remission in Patients with Rheumatoid Arthritis
Cynthia Crowson, Chanakya Kodishala, Tina Gunderson, Atkinson Elizabeth, Vanessa Kronzer, John Davis, Courtney Arment, Delamo Bekele, Thomas Mason, Lynne Peterson, Kerry Wright and Elena Myasoedova, Mayo Clinic, Rochester, MN
Background/Purpose: Seropositivity has historically been associated with poor disease outcomes in patients with rheumatoid arthritis (RA). Seronegative RA is on the rise and is associated…
Abstract Number: 1260 • ACR Convergence 2023
Optimal Approaches for Reducing Depressive Symptoms in Rheumatoid Arthritis Patients Based on Psychological Interventions: A Systematic Review and Network Meta-analysis
Zhang Lijuan and Wu Beiwen, Shanghai Jiao Tong University School of Medicine, Shanghai, China
Background/Purpose: In recent years, numerous psychological interventions for rheumatoid arthritis (RA) patients have been developed. However, it remains unclear which psychological interventions are effective and…
Abstract Number: 1104 • ACR Convergence 2023
Dotinurad, a Potent and Selective Uricosuric Agent, Exhibited Promising Pharmacokinetics and Pharmacodynamic Profiles to Significantly Reduce Serum Urate Levels Following Once Daily Dosing in Healthy U.S. Subjects in a Phase 1 Clinical Trial
Scott Baumgartner, Raymond Zheng, Mark Harnett and Jay Kranzler, Urica Therapeutics Inc., New York, NY
Background/Purpose: Dotinurad is a potent and selective URAT1 inhibitor that has been approved as a once-daily drug for the treatment of hyperuricemia with or without…
Abstract Number: 1099 • ACR Convergence 2023
Improving Hydroxychloroquine Dosing and Eye Screening Compliance in Patients with Connective Tissue Disorder
Maria Salgado Guerrero¹ and Angelo Gaffo², ¹University of Alabama at Birmingham, Birmingham, AL, ²Division of Clinical Immunology and Rheumatology, University of Alabama at Birmingham, AL; Birmingham VA Medical Center, Birmingham, AL
Background/Purpose: Hydroxychloroquine (HCQ) is a key treatment for patients with lupus and other rheumatic diseases. To minimize the risk of retinal toxicity, the American College…
Abstract Number: 1146 • ACR Convergence 2023
Gene X Environment Paradigm: Exemplified by Selected Cases of Autoinflammatory Diseases
Qingping Yao and Peter Gorevic, Stony Brook University, Stony Brook, NY
Background/Purpose: The current scientific opinion holds that gene and environment (G X E) interactions contribute to certain human diseases. Systemic autoinflammatory diseases (SAIDs) are usually…
Abstract Number: 1139 • ACR Convergence 2023
From Skin to Bone Lesions: A Pioneer Study Unraveling the Underdiagnosis of SAPHO Syndrome in the Dominican Republic
Leeany Maletta¹, Diana Jimenez² and Rosanna de Jesus³, ¹UNIBE School of Medicine, San Antonio, TX, ²UNIBE School of Medicine, Miami, FL, ³Hospital General Plaza de la Salud, Distrito Nacional, Dominican Republic
Background/Purpose: SAPHO syndrome is a rare chronic inflammatory condition that affects the skin and osteoarticular structures. Despite being first described over 30 years ago, it…
Abstract Number: 1268 • ACR Convergence 2023
Clinical Characteristics of Patients with Rheumatoid Arthritis (RA) Who Rate Their Global Assessment of Disease Activity Substantially Lower Than Their Physicians (Negative Discordance) Based on a Large RA Database in Japan: A Rare but Important Subgroup
Tetsuji Sawada¹, Susumu Nishiyama², Shohei Yamashita³, Toshihiro Matsui⁴ and Shigeto Tohma⁵, ¹Tokyo Medical University Hospital, Shinjuku Tokyo, Japan, ²Kurashiki Medical Center, Kurashiki, Japan, ³Tokyo Medical University Hospital, Shinjuku, Japan, ⁴NHO Sagamihara National Hospital, Kanagawa, Japan, ⁵NHO Tokyo National Hospital, Dallas, TX
Background/Purpose: Discordance between patient global assessment (PGA) and physician global assessment (PhGA) regarding the disease activity of rheumatoid arthritis (RA) can be divided into three…
Abstract Number: 1277 • ACR Convergence 2023
Relationship Between Quality of Life and the Region of the Affected Joints in Japanese Patients with Rheumatoid Arthritis: A Cross-sectional Study
Kenichiro Tokunaga¹, Takahiro Nishino², Hideto Oshikawa¹, Toshihiro Matsui³ and Shigeto Tohma⁴, ¹Japanese Red Cross Kumamoto Hospital, Kumamoto, Japan, ²National Hospital Organization Sagamihara National Hospital, Kanagawa, Japan, ³NHO Sagamihara National Hospital, Kanagawa, Japan, ⁴NHO Tokyo National Hospital, Dallas, TX
Background/Purpose: This clinical study aimed to investigate the relationship between affected joints and the quality of life (QOL) in patients with rheumatoid arthritis (RA) in…
Abstract Number: 1263 • ACR Convergence 2023
Depression and Anxiety Risk Assessment in Patients with Rheumatic Diseases
Luis Vega Sevilla¹, Miguel Villarreal-Alarcon², Diana Paola Flores-Gutierrez³, Maria Corral-Trujillo⁴, Ricardo Juarez⁴, Ivan Hernandez Galarza⁵, Jesus Alberto Cardenas-De la Garza⁶ and Dionicio A. Galarza-Delgado², ¹Hospital Universitario UANL, Garcia, Mexico, ²Hospital Universitario UANL, Monterrey, Mexico, ³Hospital Universitario "Dr. José Eleuterio González", Monterrey, Mexico, ⁴Universidad Autónoma de Nuevo León, Monterrey, Mexico, ⁵University Hospital, UANL, San Pedro Garza Garcia, Mexico, ⁶Hospital Universitario "Dr. José Eleuterio González", San Nicolas, Mexico
Background/Purpose: Depression is one of the most common psychiatric comorbidities in patients with rheumatic diseases. A study has shown that almost a third of patients…
Abstract Number: 1270 • ACR Convergence 2023
Identification of Subclinical Atherosclerosis by Six Cardiovascular Risk Calculators in Rheumatoid Arthritis Patients
Natalia Guajardo-Jauregui¹, José Ramón Azpiri-López², Dionicio A. Galarza-Delgado², Iris Colunga², Jesus Alberto Cardenas-De la Garza³ and Rosa Arvizu-Rivera⁴, ¹Hospital Universitario Dr. José Eleuterio González, Monterrey, Mexico, ²Hospital Universitario UANL, Monterrey, Mexico, ³Hospital Universitario "Dr. José Eleuterio González", San Nicolas, Mexico, ⁴Hospital Universitario "Dr. José Eleuterio Gonzalez", Escobedo, Mexico
Background/Purpose: Current EULAR recommendations for cardiovascular risk (CVR) assessment in rheumatoid arthritis (RA) patients indicate that the CVR evaluation should be performed according to national…
Abstract Number: 1269 • ACR Convergence 2023
The Impact of Sex, Serostatus, and Smoking on Risk for Rheumatoid Arthritis-associated Interstitial Lung Disease Subtypes
Gregory McDermott¹, Keigo Hayashi¹, Pierre-Antoine Juge², Ritu Gill¹, Suzanne Byrne¹, Staci Gagne¹, Kathleen Vanni¹, Emily Kowalski¹, Grace Qian¹, Katarina Bade³, Alene Saavedra¹, Yumeko Kawano¹, Michael Diiorio³, Taylor Wolfgang¹, Edy Kim¹, Paul Dellaripa³, Michael Weinblatt⁴, Nancy Shadick³, Tracy J. Doyle¹ and Jeffrey Sparks⁵, ¹Brigham and Women's Hospital, Boston, MA, ²Division of Rheumatology, Inflammation, and Immunity Brigham & Women's Hospital, Boston, MA, ³Brigham and Women's Hospital, Boston, MA, ⁴Harvard Medical School, Waban, MA, ⁵Division of Rheumatology, Inflammation, and Immunity, Brigham and Women’s Hospital and Harvard Medical School, Boston, MA
Background/Purpose: RA-associated interstitial lung disease (RA-ILD) is a heterogenous condition encompassing multiple subtypes with varying histopathology, prognosis, and potential treatment options. The most common RA-ILD…
Abstract Number: 1119 • ACR Convergence 2023
Preliminary Descriptive Analysis of the RADIAL Cohort Study About the Prevalence and the Clinical Characteristics of Patients with CPPD in Daily Clinical Practice
Silvia Sirotti¹, Joao Madruga-Dias², Antonella Adinolfi³, Garifallia Sakellariou⁴, Davide Rozza⁵, Greta Carrara⁵, Gianpiero Landolfi⁵, Carlo Alberto Scire⁵, Annamaria Iagnocco⁶ and Georgios Filippou¹, ¹IRCCS Galeazzi - Sant'Ambrogio Hospital, Milan, Italy, ²Centro Hospitalar do Médio Tejo, NOVA Medical School, Lisbon, Portugal, ³Rheumatology Unit, Grande Ospedale Metropolitano Niguarda, Milano, Italy, ⁴Department of Internal Medicine and Therapeutics, Università di Pavia, Istituti Clinici Scientifici Maugeri IRCCS, Pavia, Italy, ⁵Società Italiana di Reumatologia, Epidemiology Research Unit, Milan, Italy, ⁶University of Turin, Roma, Italy
Background/Purpose: The RADIAL study is aimed to evaluate the performance of a composite approach, based on clinical, laboratory and ultrasound (US) data in the differential…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].